HODHBt
Based on 1 Customer Validation
HODHBt (HOOBt) inhibits STAT5-SUMO interaction by blocking SUMOylation of phosphorylated STAT5. HODHBt enhances the magnitude of IL-15 signaling and significantly increases the natural killer (NK) cell cytotoxicity phenotype and function and the generation of cytokine-induced memory-like (CIML) natural killer (NK) cells. HODHBt can be used for research of HIV-infection and cancer.
For research use only. We do not sell to patients.
- Purity : 99.34%
- CAS No.: 28230-32-2
- Formula: C7H5N3O2
- Molecular Weight:163.13
-
Storage:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
-
Solvent & Solubility
- Protocols
- Purity & Documentation
- References
-
Help & FAQs
-
HY-Y1703
HATUPeptide Coupling Reagent -
HY-Y0912
HBTUImmunological Sensitizer -
HY-W010951
HCTUBiochemical Reagent -
HY-Y1191
EEDQCarboxylate Activator -
HY-D0178
1-Ethyl-(3-dimethylaminopropyl)carbodiimide hydrochlorideCarbodiimide Reagent -
HY-D0177
(Benzotriazol-1-yloxy)tripyrrolidinophosphonium hexafluorophosphatePeptide Coupling Reagent -
HY-Z0275
HOATPeptide Bond-forming Reagent -
HY-Y0973
BOP hexafluorophosphatePhosphonium-Type Condensing Agent -
HY-W011412
TSTUBiochemical Assay Reagent
Biological Activity
Description
IC50 & Target
[1]|
STAT5 |
In Vitro
HODHBt (100 μM; 24 h, and 48 h respectively) increases IL-15-mediated STAT phosphorylation in NK cells and enhances the cytotoxic profile of NK cells[1].
HODHBt (100 μM; 24 h) enhances IL-15-mediated (100 ng/mL) cytotoxicity of NK cells against HIV-infected cells (K562 cells)[1].
HODHBt (100 μM; 24 h) enhances IL-15-mediated (100 ng/mL, 6 h) cytotoxicity of NK cells against cancer cell lines (A2780 and U877; OCILy1 and OCILy10)[1].
HODHBt (100 μM; 7 d) results in enhanced memory response upon recall in generation of human CIML NK cells in vitro[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
Chemical Information
-
CAS No. 28230-32-2
-
Appearance Solid
-
Molecular Weight 163.13
-
Formula C7H5N3O2
-
Color White to off-white
-
SMILES
O=C1N(O)N=NC2=CC=CC=C12
-
Synonyms
HOOBt
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month
Solvent & Solubility
In Vitro:
DMSO : 50 mg/mL (306.50 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
In Vivo:
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 4.17 mg/mL (25.56 mM); Clear solution
This protocol yields a clear solution of ≥ 4.17 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (41.7 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: 4.17 mg/mL (25.56 mM); Clear solution; Need ultrasonic
This protocol yields a clear solution of 4.17 mg/mL.
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (41.7 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
In Vivo Dissolution Calculator
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL.
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Protocols
-
Research Protocol for Infectious Diseases
Infectious-disease experiments test how pathogens interact with host barriers, innate immune receptors, inflammatory signaling, pathogen replication, and tissue injury; pattern-recognition receptors such as TLRs, RIG-I-like receptors, NOD-like receptors, and inflammasomes detect microbial molecules and activate NF-κB, interferon, and cytokine responses. The central hypothesis is that infection severity reflects the balance between pathogen burden and host response: protective inflammation restricts pathogen growth, whereas excessive or mislocalized inflammation contributes to tissue damage and disease phenotype. Unresolved questions include which host pathways are protective versus pathogenic, why some infection models fail to translate to human disease, and which combined readouts best predict clinically relevant infection outcomes.
-
Cell Cytotoxicity Assay
Cytotoxicity assays are usually based on the assessment of cell membrane damage, which can also be indirectly detected by measuring cell viability. Detection methods include MTT assay, CKK-8 assay, LDH assay and ATP assay, etc.
-
Mammalian live/dead viability and cytotoxicity staining
Live/dead viability and cytotoxicity staining assays are based on the simultaneous detection of intracellular esterase activity in metabolically active (viable) cells and membrane integrity loss in non-viable cells. In commonly used dual-staining approaches, membrane-permeant fluorogenic substrates are converted by intracellular esterases into fluorescent products in live cells, while impermeant DNA-binding dyes selectively enter cells with compromised plasma membranes and label nucleic acids in dead or dying cells, enabling discrimination between viable and non-viable populations by fluorescence microscopy or flow cytometry.
-
Research Protocol for Inflammation-related Diseases
The NLRP3 inflammasome is a cytosolic innate immune signaling platform that integrates priming signals and danger-signal activation to promote caspase-1 activation, maturation of IL-1β and IL-18, and gasdermin D-mediated pyroptotic cell death. The core experimental logic is to determine whether inflammatory disease phenotypes are driven by increased NLRP3 expression, ASC-containing inflammasome assembly, caspase-1 cleavage, GSDMD cleavage, and extracellular release of IL-1β/IL-18 rather than by nonspecific cell injury alone. The pathway is strongly linked to inflammation-related disease phenotypes because monosodium urate crystals activate NALP3/NLRP3 inflammasome signaling in gout-like crystal inflammation, cholesterol crystals activate NLRP3 inflammasomes in atherogenesis models, and DSS-induced intestinal inflammation has been reported to involve NLRP3 inflammasome activity. However, experimental colitis studies also show context-dependent protective effects of NLRP3 inflammasome co
-
Cell Viability Determination by MTT Colorimetric Assay
The following protocol uses the MTT colorimetric assay as a classic literature-established method for assessing cell viability/metabolic activity in cultured mammalian cells. MTT[3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide] is reduced by metabolically active cells to a colored formazan product; the amount of formazan is quantified spectrophotometrically and provides an indirect measure of metabolically active viable cells. Importantly, MTT reduction reflects cellular oxidoreductase/metabolic activity rather than an absolute direct count of living cells, so changes in cellular metabolism can alter the signal independently of cell number.
Purity & Documentation
-
Data Sheet (274 KB)
-
SDS (771 KB)
- English - EN (771 KB)
- Français - FR (771 KB)
- Deutsch - DE (771 KB)
- Norwegian - NO (771 KB)
- Español - ES (771 KB)
- Swedish - SV (771 KB)
- Italian - IT (771 KB)
- Korean - KR (771 KB)
- Portuguese - PT (771 KB)
-
Handling Instructions (2659 KB)
References
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 6.1301 mL | 30.6504 mL | 61.3008 mL | 153.2520 mL |
| 5 mM | 1.2260 mL | 6.1301 mL | 12.2602 mL | 30.6504 mL | |
| 10 mM | 0.6130 mL | 3.0650 mL | 6.1301 mL | 15.3252 mL | |
| 15 mM | 0.4087 mL | 2.0434 mL | 4.0867 mL | 10.2168 mL | |
| 20 mM | 0.3065 mL | 1.5325 mL | 3.0650 mL | 7.6626 mL | |
| 25 mM | 0.2452 mL | 1.2260 mL | 2.4520 mL | 6.1301 mL | |
| 30 mM | 0.2043 mL | 1.0217 mL | 2.0434 mL | 5.1084 mL | |
| 40 mM | 0.1533 mL | 0.7663 mL | 1.5325 mL | 3.8313 mL | |
| 50 mM | 0.1226 mL | 0.6130 mL | 1.2260 mL | 3.0650 mL | |
| 60 mM | 0.1022 mL | 0.5108 mL | 1.0217 mL | 2.5542 mL | |
| 80 mM | 0.0766 mL | 0.3831 mL | 0.7663 mL | 1.9157 mL | |
| 100 mM | 0.0613 mL | 0.3065 mL | 0.6130 mL | 1.5325 mL |
HODHBt Related Classifications
HY-Y0493 Related Classifications
Powered by Bioz